Leukemia Research Foundation awards $1.3 million in grants

Leukemia Research Foundation awarded $1.3 million in grants to support new investigators who are conducting studies related to blood cancer.

Each of the 13 recipients will receive 1-year grants worth $100,000.

Leukemia diagnois text with pills and IV treatments — *Source: Adobe Stock.*

“Providing grants to new investigators is critically important,” foundation executive director Kevin Radelet said in a press release. “New Investigators are a key niche of innovative scientists who are beginning to establish their own laboratories and are no longer under the tutelage of a senior scientist mentor. The funding enables new investigators to act on their ideas, and try new procedures and experiments that will lead to significant breakthroughs.”

Grant recipients and their projects are:

Jeevisha Bajaj, PhD, of Rochester University — Role of SLC6A6 in aggressive myeloid leukemia;
Triona Ni Chonghaile, PhD, BSc, of Royal College of Surgeons in Ireland — Identifying and epigenetically inducing BCL-2 dependence in multiple myeloma;
Sergi Cuartero, PhD, of Josep Carreras Leukaemia Research Institute in Spain — Identifying novel transcriptional vulnerabilities in myelodysplastic syndrome with cohesin mutations;
Heiko Konig, MD, PhD, of Indiana University — A novel approach to target drug resistant acute myeloid leukemia cells;
Bridget Marcellino, MD, PhD, of Icahn School of Medicine at Mount Sinai — Enhancing natural killer cell recognition of leukemic cells;
Fabiana Perna, MD, PhD, of Indiana University — Interrogation of the leukemia cell surfaceome for immune-targeting;
Yana Pikman, MD, of Dana-Farber Cancer Institute — Novel combination strategy for targeting one-carbon folate metabolism for T-cell acute lymphoblastic leukemia therapy;
Giovanni Roti, MD, PhD, of University of Parma in Italy — Targeting NOTCH1 trafficking vulnerabilities in T-cell ALL;
Simone Sidoli, PhD, of Albert Einstein College of Medicine — Accessible heterochromatin as new target against AML development;
George Souroullas, PhD, of Washington University — Understanding the oncogenic mechanisms and chromatin interactions of EZH2 mutations in lymphoma;
Liling Wan, PhD, of University of Pennsylvania Perelman School of Medicine — Targeting the chromatin reader protein ENL in acute leukemias;
Siao-Yi Wang, MD, PhD, of Loyola University Cardinal Bernardin Cancer Center — Engineering CD19-specific chimeric antigen receptor T cells without inducing cell division or differentiation; and
Yibin Yang, PhD, of Fox Chase Cancer Center — Investigating and therapeutic targeting of the IL1R1-MyD88 pathway in anaplastic large cell lymphoma.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Leukemia Research Foundation awards $1.3 million in grants

Related Content